Virtual Library

Start Your Search

Esra Gümüştepe



Author of

  • +

    P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.01-40 - Prognostic Importance of Sarcopeni and Inflammatory Statements in Stage III Non Small Cell Lung Carcinoma (ID 13727)

      16:45 - 18:00  |  Author(s): Esra Gümüştepe

      • Abstract
      • Slides

      Background

      Sarcopenia is characterized by progressive loss of skeletal muscle mass, muscle strength and physical performance. Systemic inflammation is thought to contribute to sarcopenia. Current retrospective evidence suggests that sarcopenia is an independent prognostic value on overall survival(OS).

      In this study, we aimed to investigate the prognostic significance of sarcopenia and inflammatory markers in stage III small cell lung cancer (NSCLC).

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Eighty-three patients with stage III NSCLC undergoing definitive chemoradiotherapy in our clinic between April 2014 and August 2017 were evaluated. The cross-sectional area of muscle at the level of the third lumbar vertebra (L3) was measured using of radiotherapy planning CT images. Sarcopenia was defined as a L3 muscle index of less than 55 cm2/m2 for men and of less than 39 cm2/m2 for women as proposed by international consensus of cancer cachexia. Systemic inflammatory markers investigated included serum lactate dehydrogenase (LDH), neutrophil: lymphocyte ratio (NLR), C-reactive protein (CRP), and albumin(alb) . Relations between variables were determined by Pearson Chi Square and FischerExact Test. Risk factors affecting dependent variables were determined by CoxRegresson Analysis.

      4c3880bb027f159e801041b1021e88e8 Result

      Seventy-five (90%) of the patients were male and 8 (10%) were female. The number of sarcopenic patients was 52 (62.6%). The mean age was higher in sarcopenic patients (68.3 ± 9.7 vs 63.7 ± 9.4, p = 0.037). There was no statistically significant difference between the groups with and without sarcopenia in the ratio of low albumin level, LDH height, N / L ratio. Mean survival was 18.14 months (2-48 months). In sarcopenic patients, OS was 17.2 months, while non-sarcopenic patients were 19.58 months (p = 0.310). When the effects on general survival were examined, it was found statistically significant that the presence of sarcopenia (p = 0.016), age (p = 0,001), low alb level (p = 0,009), N / L ratio is higher than 4 (p = 0,003). Multivarible Cox regression analyzes showed independent prognostic significance in survival with RT dose (HR (95% CI) = 1,2; p = 0.001), low albumin level (HR (95% CI) = 2.42; p = 0.007) and age (HR(95%CI)=1,03; p=0,044).

      8eea62084ca7e541d918e823422bd82e Conclusion

      In our study, the presence of sarcopenia in patients with stage III definitive KTRT NSCLC, as well as the LOW alb ratio and N / L ratio of inflammatory markers was found to be a significant prognostic factor for OS. We aim to investigate the prognostic significance of sarcopenia 'cutoff' value for Turkey with a prospective, multicenter, larger group of patients.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.